表紙
市場調查報告書

大流行後醫療保健全球市場展望:2020

Post-pandemic Global Healthcare Market Outlook, 2020

出版商 Frost & Sullivan 商品編碼 951774
出版日期 內容資訊 英文 104 Pages
商品交期: 最快1-2個工作天內
價格
大流行後醫療保健全球市場展望:2020 Post-pandemic Global Healthcare Market Outlook, 2020
出版日期: 2020年07月09日內容資訊: 英文 104 Pages
簡介

主要的醫療保健提供者已採取降低風險的措施,以優先考慮從大流行中恢復的機會並重建股東的信心。儘管仍然存在對測試,PPE和呼吸機的短期需求,並且為COVID-19尋找疫苗和治療方法的競爭仍在繼續,但是醫療保健公司瞭解對於消費者而言,日常的新意義需要製定應急計劃,以防止將來發生醫療危機。

本報告調查和分析了大流行後的全球醫療保健市場,並提供了有關增長環境,主要趨勢,情景和市場前景的系統信息。

目錄

執行摘要

成長環境

  • 潛在的COVID-19情景
  • 主要預測標準
  • 兩種情況下的收入預測
  • 5大醫療保健行業預測

不斷變化的商業和經濟情景

  • 按地區分的GDP增長率:地緣政治衝擊
  • 按地區分的GDP增長率:地緣政治衝擊的趨勢
  • 政府對COVID-19的回應
  • COVID-19對全球GDP增長的影響
  • 討論COVID-19對全球GDP增長的影響
  • 商業刺激措施
  • COVID-19的刺激趨勢分析
  • 主要國家的COVID-19刺激趨勢分析
  • COVID-19對行業的影響:反應,恢復,成功
  • 構成醫療保健業務生態系統的因素
  • 醫療保健行業面臨的主要挑戰
  • COVID-19對醫療保健行業的影響

全球醫療保健市場展望

  • 全球醫療保健市場收入
  • 關於全球醫療市場收入預測的討論
  • COVID-19回應:影響評估
  • 刺激全球醫療保健:先進市場
  • 刺激全球醫療保健:新興市場
  • 全球醫療保健公司評估:影響評估
  • 生命科學公司:應對和增長計劃
  • 圖像診斷設備公司:響應和增長計劃
  • 醫療設備/運送公司:應對和增長計劃
  • 醫療保健IT公司:應對措施和增長計劃

藥物和生物技術的前景

  • 市場快照:製藥/生物技術
  • 按產品細分劃分的戰略問題
  • 主要預測趨勢
  • 預測
  • 用於臨床試驗的IT解決方案
  • 推薦的行為(C2A)

體外診斷的前景

  • 市場概況:體外診斷
  • 按產品細分的戰略問題
  • 主要預測趨勢
  • 預測
  • 對COVID-19 POCT的需求
  • 推薦的行為(C2A)

醫療技術展望

  • 市場概況:醫療技術
  • 按產品細分的戰略問題
  • 主要預測趨勢
  • 預測
  • 緊急醫療服務的優先級
  • 推薦的行為(C2A)

醫療診斷成像設備的前景

  • 市場概況:醫學診斷成像設備
  • 按產品細分的戰略問題
  • 主要預測趨勢
  • 預測
  • 創新的客戶-供應商合作夥伴關係和PPP模式
  • 推薦的行為(C2A)

醫療保健IT前景

  • 市場概況:IT保健
  • 按產品細分劃分的戰略問題
  • 主要預測趨勢
  • 預測
  • 遠程醫療
  • 推薦的行為(C2A)

要點:戰略要務

  • 結論
  • 流行病限制醫療保健公司
  • 降低風險戰略的時間表
  • 響應,重置,反彈

下一步

附錄:增長管道引擎

目錄
Product Code: MF6E-52

Stakeholders to Focus on Resource Optimization, New Growth Segments, and Cost Rationalization in a New Era of 'Healthcare Preparedness'

Every year, the team of futurists, analysts, and consultants in Frost & Sullivan's Transformational Healthcare Group comes together to render a comprehensive analysis to predict the themes, technologies, and global forces that will define the next 12 to 18 months (future) for the healthcare industry. In light of the lessons learned from the COVID-19 pandemic and the changing economic and business scenario, Frost & Sullivan has re-visited predictions and identified the top growth opportunities for companies to survive the remainder of 2020. Among the considerations:

  • Disrupted clinical trials and the subsequent delay in drug launches will pave the way for fully virtual trials, and hybridization of patient recruitment, retention, and monitoring will become pervasive.
  • An increase in point-of-care testing for infectious diseases is inevitable. With the looming change in service models, alternate testing sites such as pharmacies will become permanent ecosystem participants.
  • The supply of ventilators and critical care monitoring devices across regions has been uneven during the pandemic, but embedded analytics systems will revive the mature monitoring devices segment post-pandemic.
  • A resumption in imaging for the backlog of elective procedures in Q3 and Q4 2020 will be met by teleradiology and artificial intelligence-based solutions gaining from new investments. Scale-up in capacity, flexible payment options, and redistribution of the workload to manage deferrals will determine partnerships.
  • A tenfold increase in virtual consultations by healthcare providers is laying the foundation for the new normal. Reimbursement, physician training, and platform scalability will be key to recalibrate care delivery.

Amid the uncertainty, leading healthcare players are adopting risk-mitigation measures and reprioritizing opportunities to recover from the pandemic and rebuild shareholder confidence. While the short-term demand for testing, personal protective equipment, and ventilators remains, and the race to find a vaccine and treatment for COVID-19 continues, healthcare companies must understand what the new normal means for the consumer and prepare a contingency plan to prevent a future healthcare crisis.

As part of this research deliverable, Frost & Sullivan provides bold perspectives for the global healthcare market in 2020. The segments covered include pharmaceuticals and biotech, in vitro diagnostics, medical technologies, medical imaging, and healthcare IT. The analysis captures segment and regional trends and presents predictions for the remainder of 2020. The study provides guidance on where to find the greatest opportunities for expansion in the "Age of the Bio-Economy," which will have significant impact and transformation on economies, societies, and lives.

Table of Contents

Executive Summary

  • Covid-19 Impact Summary
  • Introduction: A New Era of Healthcare Preparedness
  • Research Scope and Segmentation
  • Key Questions this Study will Answer

Growth Environment

  • Potential COVID-19 Scenarios
  • Key Forecast Criteria
  • Revenue Forecasts in 2 Scenarios
  • Top 5 Predictions for the 2020 Healthcare Industry

Changing Business & Economic Scenario

  • Regional GDP Growth Rate: Geopolitical Shocks
  • Regional GDP Growth Rate: Geopolitical Shock Trends
  • Regional GDP Growth Rate: Geopolitical Shock Trends (continued)
  • Government Response to COVID-19
  • COVID-19 Impact on World GDP Growth
  • COVID-19 Impact on World GDP Growth Discussion
  • Economic Stimulus Measures
  • COVID-19 Stimulus Trend Analysis
  • COVID-19 Stimulus Trend Analysis in Selected Countries
  • COVID-19 Impact on Industries: Struggling, Surviving, and Thriving
  • Forces Shaping the Healthcare Business Ecosystem
  • Key Challenges Faced by the Healthcare Industry
  • COVID-19 Impact on the Healthcare Industry

Global Healthcare Market Outlook for 2020

  • Global Healthcare Market Revenue: 2019 and 2020
  • Global Healthcare Market Revenue Forecast Discussion
  • Global Healthcare Market Revenue Forecast Discussion (continued)
  • COVID-19 Response Efforts: Impact Assessment
  • 2020 Global Healthcare Stimulus: Developed Markets
  • 2020 Global Healthcare Stimulus: Developed Markets (continued)
  • 2020 Global Healthcare Stimulus: Emerging Markets
  • 2020 Global Healthcare Stimulus: Emerging Markets (continued)
  • Global Healthcare Company Valuations: Impact Assessment
  • Life Science Companies: Response and Growth Plans
  • Life Science Companies: Response and Growth Plans (continued)
  • Imaging Companies: Response and Growth Plans
  • Imaging Companies: Response and Growth Plans (continued)
  • Medical Device/Delivery Companies: Response and Growth Plans
  • Medical Device/Delivery Companies: Response and Growth Plans (continued)
  • Healthcare IT Companies: Response and Growth Plans
  • Healthcare IT Companies: Response and Growth Plans (continued)

Pharmaceuticals and Biotechnology Outlook

  • 2020 Market Snapshot: Pharmaceuticals and Biotechnology
  • Strategic Imperatives by Product Segment
  • Key Forecast Trends
  • Prediction: By the End of 2020, 33% of Global Clinical Trials Will Be Disrupted, Putting $3 Billion in New Product Revenue At Risk
  • Clinical Trial IT Solutions Enabling Virtualization
  • Companies to Action

In Vitro Diagnostics Outlook

  • 2020 Market Snapshot: In Vitro Diagnostics
  • Strategic Imperatives by Product Segment
  • Key Forecast Trends
  • Prediction: Alternate Testing Sites to Change the POCT Service Paradigm for the $5 Billion Infectious Diseases Market
  • Demand for COVID-19 POCT
  • Companies to Action

Medical Technologies Outlook

  • 2020 Market Snapshot: Medical Technologies
  • Strategic Imperatives by Product Segment
  • Key Forecast Trends
  • Prediction: 3X Ventilator Surplus and Remote Monitoring Will Redefine the Non-hospital and Home Critical Care Model
  • Resetting Priority for Critical Care Medicine
  • Companies to Action

Medical Imaging Equipment Outlook

  • 2020 Market Snapshot: Medical Imaging Equipment
  • Strategic Imperatives by Product Segment
  • Key Forecast Trends
  • Prediction: Informatics and AI Solutions Addressing Workflow Automation, and Operational Analytics Will Witness 100% Growth In 2020
  • Acceleration of Innovative Customer-Vendor Partnership and PPP Models
  • Companies to Action

Healthcare IT Outlook

  • 2020 Market Snapshot: Healthcare IT
  • Strategic Imperatives by Product Segment
  • Key Forecast Trends
  • Prediction: Virtual Consultations Will Witness Greater Than 100% Growth in the United States
  • Telehealth as a Mainstream Delivery Model
  • Companies to Action
  • Companies to Action (continued)

Key Takeaways: Strategic Imperatives for the Road to Recovery

  • Conclusions
  • Pandemic Driving Restructuring of Healthcare Companies
  • Risk Mitigation Strategy Timeline
  • Respond, Reset, and Rebound

Next Steps

  • COVID-19 Healthcare Strategy Partnership
  • Take the COVID-19 Growth Pipeline Diagnostic
  • List of Exhibits
  • List of Exhibits (continued)
  • Legal Disclaimer

Appendix: Growth Pipeline Engine™

  • About the Growth Pipeline Engine™
  • Market Definition: Pharmaceuticals and Biotechnology
  • Market Definition: In Vitro Diagnostics
  • Market Definition: Medical Technologies
  • Market Definition: Medical Technologies (continued)
  • Market Definition: Medical Imaging Equipment
  • Market Definition-Healthcare IT